ZA201707373B - Tpp1 formulations and methods for treating cln2 disease - Google Patents
Tpp1 formulations and methods for treating cln2 diseaseInfo
- Publication number
- ZA201707373B ZA201707373B ZA2017/07373A ZA201707373A ZA201707373B ZA 201707373 B ZA201707373 B ZA 201707373B ZA 2017/07373 A ZA2017/07373 A ZA 2017/07373A ZA 201707373 A ZA201707373 A ZA 201707373A ZA 201707373 B ZA201707373 B ZA 201707373B
- Authority
- ZA
- South Africa
- Prior art keywords
- tpp1
- formulations
- methods
- cln2 disease
- treating cln2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158789P | 2015-05-08 | 2015-05-08 | |
| US201662300171P | 2016-02-26 | 2016-02-26 | |
| PCT/US2016/031074 WO2016182862A1 (en) | 2015-05-08 | 2016-05-05 | Tpp1 formulations and methods for treating cln2 disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201707373B true ZA201707373B (en) | 2019-02-27 |
Family
ID=57222195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/07373A ZA201707373B (en) | 2015-05-08 | 2017-10-30 | Tpp1 formulations and methods for treating cln2 disease |
Country Status (25)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| US11726091B2 (en) | 2017-04-03 | 2023-08-15 | The Regents Of The University Of California | Compositions and methods of diagnosing pancreatic cancer |
| EP3684463B1 (en) | 2017-09-19 | 2025-05-14 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| WO2019133997A1 (en) | 2017-12-31 | 2019-07-04 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| CN113382683A (zh) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | 改善睡眠的系统和方法 |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US20220381784A1 (en) * | 2019-06-07 | 2022-12-01 | The Regents Of The University Of California | Systems comprising substrates and methods of using the same for detection of pancreatic cancers |
| HRP20240871T1 (hr) * | 2019-08-29 | 2024-10-11 | Biomarin Pharmaceutical Inc. | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata |
| IT201900023142A1 (it) * | 2019-12-05 | 2021-06-05 | Sifi Spa | Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus |
| US20230060797A1 (en) * | 2021-09-02 | 2023-03-02 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
| CN117731312A (zh) | 2022-09-13 | 2024-03-22 | 上海联影医疗科技股份有限公司 | 一种医学图像的扫描方法和系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| AR039352A1 (es) * | 2001-05-18 | 2005-02-16 | Solvay Pharm Gmbh | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. |
| AU2002362436A1 (en) * | 2001-10-03 | 2003-04-14 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
| CA2388659A1 (en) * | 2002-05-31 | 2003-11-30 | Mcgill University | Phospholipase a2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20110166074A1 (en) | 2006-10-18 | 2011-07-07 | Cornell Research Foundation, Inc. | Cln2 treatment of alzheimer's disease |
| WO2008157308A2 (en) | 2007-06-13 | 2008-12-24 | Wayne State University Board Of Governors | A zwitterion solution for low-volume therapeutic delivery |
| EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| WO2012015910A2 (en) * | 2010-07-28 | 2012-02-02 | Allon Therapeutics Inc. | Use of adnf polypeptides for treating neurodegenerative diseases |
| JP2014520159A (ja) * | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法 |
| US20150000936A1 (en) * | 2011-12-13 | 2015-01-01 | Schlumberger Technology Corporation | Energization of an element with a thermally expandable material |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| DK3115372T3 (da) * | 2012-11-27 | 2019-06-11 | Biomarin Pharm Inc | Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf |
| US9750712B2 (en) | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| EP3024497B1 (en) * | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| TWI752907B (zh) | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
-
2016
- 2016-04-27 TW TW105113155A patent/TWI752907B/zh active
- 2016-05-05 MX MX2017014204A patent/MX2017014204A/es unknown
- 2016-05-05 HR HRP20171905AA patent/HRP20171905B1/hr active IP Right Grant
- 2016-05-05 SI SI201631792T patent/SI3294345T1/sl unknown
- 2016-05-05 SM SM20240026T patent/SMT202400026T1/it unknown
- 2016-05-05 US US15/147,485 patent/US10279015B2/en active Active
- 2016-05-05 JP JP2017558434A patent/JP6931330B2/ja active Active
- 2016-05-05 RS RS20240067A patent/RS65101B1/sr unknown
- 2016-05-05 WO PCT/US2016/031074 patent/WO2016182862A1/en not_active Ceased
- 2016-05-05 EP EP16793229.2A patent/EP3294345B1/en active Active
- 2016-05-05 HU HUE16793229A patent/HUE065649T2/hu unknown
- 2016-05-05 PL PL16793229.2T patent/PL3294345T3/pl unknown
- 2016-05-05 CN CN201680025984.6A patent/CN107847615B/zh active Active
- 2016-05-05 HR HRP20240050TT patent/HRP20240050T1/hr unknown
- 2016-05-05 CN CN202210014711.9A patent/CN114225018A/zh active Pending
- 2016-05-05 ES ES16793229T patent/ES2968375T3/es active Active
- 2016-05-05 DK DK16793229.2T patent/DK3294345T3/da active
- 2016-05-05 FI FIEP16793229.2T patent/FI3294345T3/fi active
- 2016-05-05 AU AU2016262434A patent/AU2016262434B2/en active Active
- 2016-05-05 KR KR1020177032973A patent/KR102375051B1/ko active Active
- 2016-05-05 PT PT167932292T patent/PT3294345T/pt unknown
- 2016-05-05 CA CA2984448A patent/CA2984448A1/en active Pending
- 2016-05-05 RU RU2017142727A patent/RU2733464C2/ru active
- 2016-05-05 EP EP23204139.2A patent/EP4327873A3/en active Pending
- 2016-05-05 LT LTEPPCT/US2016/031074T patent/LT3294345T/lt unknown
-
2017
- 2017-10-29 IL IL255307A patent/IL255307B/en active IP Right Grant
- 2017-10-30 ZA ZA2017/07373A patent/ZA201707373B/en unknown
- 2017-11-08 CL CL2017002825A patent/CL2017002825A1/es unknown
-
2019
- 2019-03-28 US US16/368,091 patent/US10758598B2/en active Active
-
2020
- 2020-04-12 IL IL273913A patent/IL273913B2/en unknown
- 2020-07-28 US US16/941,454 patent/US11229687B2/en active Active
-
2021
- 2021-08-13 JP JP2021131875A patent/JP7421520B2/ja active Active
-
2022
- 2022-12-12 IL IL299024A patent/IL299024B2/en unknown
-
2024
- 2024-01-12 JP JP2024003133A patent/JP2024026739A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299024B2 (en) | Tripeptidyl peptidase-1 preparations and methods for treating neuronal ceroid lipofuscinosis | |
| IL265590B (en) | Formulations and methods for keratin treatment | |
| ZA201705673B (en) | Methods for treating skin | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL252819A0 (en) | Hypochlorous acid preparations and methods for treating skin diseases | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| PL3215219T3 (pl) | System do zabiegów na skórze | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| GB201519200D0 (en) | Skin care composition and method thereof | |
| ZA201707813B (en) | Composition for treating tissue lesions | |
| PL3367995T3 (pl) | Kompozycja do pielęgnacji skóry oraz jej sposób | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| IL252904A0 (en) | Methods and factors for treating diseases | |
| SG11201710686PA (en) | Hair treatment agent | |
| GB201604658D0 (en) | Treatment for pain | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| HUE061056T2 (hu) | Készítmény meddõség kezelésére nõi betegnél | |
| IL246608A0 (en) | Preparations and methods for treating heart disease | |
| GB201504413D0 (en) | Treatment of disease | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201505205D0 (en) | Treatment for pain | |
| GB201504688D0 (en) | Treatment for pain | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| GB201519207D0 (en) | Skin care composition and method thereof | |
| GB201511453D0 (en) | Treatment of alzheimer's disease |